In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Capmatinib, trade name Tabrecta. It is an oral MET inhibitor mainly used for the···【more】
Release date:2024-08-09Recommended:372
Capmatinib is an oral, selective, ATP-competitive c-Met kinase inhibitor that in···【more】
Release date:2024-08-09Recommended:393
Pemigatinib is a targeted drug that is mainly used to treat cholangiocarcinoma.H···【more】
Release date:2024-08-09Recommended:324
Capmatinib is a lung cancer drug that targets specific genetic mutations, especi···【more】
Release date:2024-08-09Recommended:402
Pemigatinibis a targeted drug for the treatment of cholangiocarcinoma and belong···【more】
Release date:2024-08-09Recommended:317
Capmatinib is a targeted therapy for the treatment of non-small cell lung cancer···【more】
Release date:2024-08-09Recommended:370
Exkivity reduces the growth of non-small cell lung cancer by binding to and inhi···【more】
Release date:2024-08-09Recommended:354
Exkivity works by binding to and blocking EGFR exon 20 insertion mutations, whic···【more】
Release date:2024-08-09Recommended:364
Exkivity was granted accelerated FDA approval in 2021 based on results from the ···【more】
Release date:2024-08-09Recommended:392
Exkivity capsules can be used by adults with non-small cell lung cancer that has···【more】
Release date:2024-08-09Recommended:283
Exkivity (mobocertinib) is a tyrosine kinase inhibitor (TKI) used to treat non-s···【more】
Release date:2024-08-09Recommended:322
Exkivity (mobocertinib) is a tyrosine kinase inhibitor (TKI) used to treat non-s···【more】
Release date:2024-08-09Recommended:314